Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: A new immuno-metabolic perspective for age-related diseases. Nat. Rev. Endocrinol. 14576-590 (2018).
Butterfield, DA & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism, and Alzheimer’s disease. Nat. Rev. Neurosci. 20148-160 (2019).
Tuven, B., Soysal, P., Unutmaz, G., Kaya, D. & Isik, AT Uric acid may protect against cognitive impairment in older adults, but only in those without risk factors cardiovascular. Exp. Gerontol. 8915-19 (2017).
Mon. et al. Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann. Common cold. Say. 75547–551 (2016).
Latourte, A., Bardin, T. & Richette, P. Uric acid and cognitive decline: a double-edged sword?. Running. Notice. Rheumatol. 30183–187 (2018).
Singh, JA & Cleveland, JD Gout and dementia in the elderly: a cohort study of health insurance claims. BMC Geriatrics 18(2018).
Moorhouse, PC, Grootveld, M., Halliwell, B., Quinlan, JG & Gutteridge, JM Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Letter 21323–28 (1987).
Fukui, T. et al. Effects of febuxostat on oxidative stress. Clin. The. 371396-1401 (2015).
Zhang, Q. et al. Allopurinol protects against ischemic insults in a mouse model of cortical microinfarction. Brain Res. 1622361–367 (2015).
Maiwald, California et al. Effect of allopurinol in addition to treatment of hypothermia in neonates with hypoxic-ischemic brain injury on neurocognitive outcomes (ALBINO): study protocol of a multicenter, parallel-group, randomized, controlled trial in blinded for superiority (Phase III). BMC Pediatr. 19210 (2019).
Singh, JA and Cleveland, JD Comparative efficacy of allopurinol versus febuxostat for preventing incident dementia in the elderly: a matched propensity analysis. Arthritis Res. The. 20167 (2018).
Latourte, A. et al. Uric acid and incident dementia at 12 years of follow-up: a population-based cohort study. Ann. Common cold. Say. 77328–335 (2018).
Scheepers, LEJM et al. Urate and risk of Alzheimer’s disease and vascular dementia: a population-based study. Alzheimer’s dementia 15754–763 (2019).
Engel, B. et al. Hyperuricemia and dementia – a case-control study. BMC Neurol 18(2018).
Erkinjuntti, T., Ostbye, T., Steenhuis, R. & Hachinski, V. The effect of different diagnostic criteria on the prevalence of dementia. N.Engl. J.Med. 3371667–1674 (1997).
Vellas, B. et al. Mapt study: A multidomain approach to prevent Alzheimer’s disease: Design and basic data. J. Prev. Alzheimer’s disease 113–22 (2014).
Andrieu, S. et al. Effect of long-term omega-3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in older adults with memory impairment (MAPT): a randomized placebo-controlled trial. Neurol Lancet 16377–389 (2017).
Richet, P. et al. 2016 update of EULAR evidence-based recommendations for the management of gout. Ann. Common cold. Say. 7629–42 (2017).
Pacher, P., Nivorozhkin, A. & Szabó, C. Therapeutic effects of xanthine oxidase inhibitors: Rebirth half a century after the discovery of allopurinol. Pharmacol Rev. 5887–114 (2006).
Slobodnick, A., Shah, B., Krasnokutsky, S. & Pillinger, MH Colchicine Update, 2017. Rheumatology (Oxford) 57i4–i11 (2018).
Kippen, I., Whitehouse, MW & Klinenberg, JR Pharmacology of uricosuric drugs. Ann. Rheum Dis. 33391–396 (1974).
Rafin, J. et al. Associations between physical activity, blood biomarkers of neurodegeneration, and cognition in healthy older adults: the MAPT study. J. Gerontol A Biol. Science. Med. Science. 761382–1390 (2021).
Johnson, RJ et al. Uric acid and chronic kidney disease: who is chasing whom?. Nephrol Dial Graft 282221-2228 (2013).
Richet, P. et al. Improving cardiovascular and renal outcomes in gout: what should we be targeting?. Nat. Rev. Rheumatol ten654–661 (2014).
Sluijs, I. et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes 643028-3036 (2015).
Massi, S. et al. The complex relationship between serum uric acid, endothelial function and small vessel remodeling in man. J. Clin. Med. 9E2027 (2020).
Khosla, UM et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 671739–1742 (2005).
Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. Jam. Soc. Nephrol 51388–1393 (2010).
Khan, AA, Quinn, TJ, Hewitt, J., Fan, Y. & Dawson, J. Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis. Age (Dordr.) 3816 (2016).
Wishart, DS et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46D1074–D1082 (2018).
Lagorce, D., Douguet, D., Miteva, MA & Villoutreix, BO Computational analysis of physicochemical and calculated ADMET properties of protein-protein interaction inhibitors. Science. representing seven(2017).
Scherrmann, JM Drug delivery to the brain via the blood-brain barrier. Vascul. Pharmacol. 38349-354 (2002).
Muir, SW et al. Allopurinol use produces potentially beneficial effects on inflammatory indices in people with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 393303–3307 (2008).
Sonnen, JA et al. Pathological correlates of dementia in a population-based longitudinal aging sample. Ann. Neurol 62406–413 (2007).
Haglund, M., Passant, U., Sjöbeck, M., Ghebremedhin, E. & Englund, E. Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int. J. Geriatr. Psychiatry 21681–687 (2006).
Gifford, KA et al. The source of cognitive impairment predicts diagnostic conversion differently in older people without dementia. Alzheimer’s dementia ten319-327 (2014).
Donohue, MC et al. The preclinical Alzheimer’s cognitive composite: measuring amyloid-related decline. JAMA Neurol 71961–970 (2014).
Stamp, LK et al. Use of allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Rheumatic arthritis 63412-421 (2011).
Jutkowitz, E., Choi, HK, Pizzi, LT & Kuntz, KM Cost effectiveness of allopurinol and febuxostat for the management of gout. Ann. Internal. Med. 161617-626 (2014).
Jeyaruban, A., Larkins, S., and Soden, M. Management of gout in general practice – a systematic review. Clin. Rheumatol 349–16 (2015).